Morgan Stanley Starts BridgeBio Pharma (BBIO) at Overweight

Morgan Stanley analyst Sean Laaman initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Overweight rating and a price target of $96.00.

The analyst comments: "Initiating coverage of BridgeBio Pharma (BBIO) with an Overweight rating and a $96 price target, implying 20%+ upside from current levels. BBIO is well- positioned as a leading rare disease company with a diversified late-stage pipeline and a commercial-stage asset (Attruby/acoramidis) in ATTR-CM, a serious heart condition that can lead to heart failure. The company is evolving into a multi- product rare disease franchise, supported by recent Phase 3 wins and upcoming regulatory catalysts. Profitability inflexion point - another "SMID to Big" candidate: We see BBIO achieving positive net income and free cash flow in 2027E. Given our forecast top- line 2025 - 2030 CAGR of +39% with relatively more modest growth in opex, our implied BBIO P/E in 2030E is a lowly 5.7x (for reference, MS US Large Cap Biopharma average 2025E P/E stands at ~14x) suggesting a compelling long-term opportunity for investors."

For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.

Shares of BridgeBio Pharma closed at $73.42 yesterday.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Roku Said To Be In Sale Talks, Including Possible Media Tie-up - Bloomberg
• AMETEK secures $7.5 billion in credit facilities for Indicor acquisition